Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies. (Q38083089)

From Wikidata

Jump to navigation Jump to search

scientific article published on 21 February 2013

Language	Label	Description	Also known as
English	Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies.	scientific article published on 21 February 2013

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23425140%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23425140%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Alexandra Boer Kimball

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23425140%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

author name string

P L Mattei

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23425140%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

K C Corey

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23425140%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

publication date

21 February 2013

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23425140%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Journal of the European Academy of Dermatology and Venereology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23425140%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

28

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23425140%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23425140%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

333-337

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23425140%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Disease severity, quality of life and health care in plaque-type psoriasis: a multicenter cross-sectional study in Germany.

1 reference

https://api.crossref.org/works/10.1111%2FJDV.12106

21 January 2018

The psychosocial impact of psoriasis: physical severity, quality of life, and stigmatization.

1 reference

https://api.crossref.org/works/10.1111%2FJDV.12106

21 January 2018

The contribution of perceptions of stigmatisation to disability in patients with psoriasis

1 reference

https://api.crossref.org/works/10.1111%2FJDV.12106

21 January 2018

Quality of life and clinical outcome in psoriasis patients using intermittent cyclosporin

1 reference

https://api.crossref.org/works/10.1111%2FJDV.12106

21 January 2018

CLinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1111%2FJDV.12106

21 January 2018

Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes.

1 reference

https://api.crossref.org/works/10.1111%2FJDV.12106

21 January 2018

Effects of alefacept on health-related quality of life in patients with psoriasis: results from a randomized, placebo-controlled phase II trial.

1 reference

https://api.crossref.org/works/10.1111%2FJDV.12106

21 January 2018

Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1111%2FJDV.12106

21 January 2018

Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial.

1 reference

https://api.crossref.org/works/10.1111%2FJDV.12106

21 January 2018

Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial.

1 reference

https://api.crossref.org/works/10.1111%2FJDV.12106

21 January 2018

Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial

1 reference

https://api.crossref.org/works/10.1111%2FJDV.12106

21 January 2018

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

1 reference

https://api.crossref.org/works/10.1111%2FJDV.12106

21 January 2018

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial.

1 reference

https://api.crossref.org/works/10.1111%2FJDV.12106

21 January 2018

Impact of efalizumab on patient-reported outcomes in high-need psoriasis patients: results of the international, randomized, placebo-controlled Phase III Clinical Experience Acquired with Raptiva (CLEAR) trial [NCT00256139].

1 reference

https://api.crossref.org/works/10.1111%2FJDV.12106

21 January 2018

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

1 reference

https://api.crossref.org/works/10.1111%2FJDV.12106

21 January 2018

Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1111%2FJDV.12106

21 January 2018

Once-weekly administration of etanercept 50 mg improves patient-reported outcomes in patients with moderate-to-severe plaque psoriasis

1 reference

https://api.crossref.org/works/10.1111%2FJDV.12106

21 January 2018

Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis.

1 reference

https://api.crossref.org/works/10.1111%2FJDV.12106

21 January 2018

Impact of adalimumab treatment on patient-reported outcomes: results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis.

1 reference

https://api.crossref.org/works/10.1111%2FJDV.12106

21 January 2018

The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study

1 reference

https://api.crossref.org/works/10.1111%2FJDV.12106

21 January 2018

A phase IIIb, multicentre, randomized, double-blind, vehicle-controlled study of the efficacy and safety of adalimumab with and without calcipotriol/betamethasone topical treatment in patients with moderate to severe psoriasis: the BELIEVE study.

1 reference

https://api.crossref.org/works/10.1111%2FJDV.12106

21 January 2018

Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use.

1 reference

https://api.crossref.org/works/10.1111%2FJDV.12106

21 January 2018

National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening.

1 reference

https://api.crossref.org/works/10.1111%2FJDV.12106

21 January 2018

Psoriasis and the risk of diabetes and hypertension: a prospective study of US female nurses

1 reference

https://api.crossref.org/works/10.1111%2FJDV.12106

21 January 2018

Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis.

1 reference

https://api.crossref.org/works/10.1111%2FJDV.12106

21 January 2018

The impact of psoriasis on the quality of life of patients from the 16-center PUVA follow-up cohort.

1 reference

https://api.crossref.org/works/10.1111%2FJDV.12106

21 January 2018

The burden of psoriasis in Canada: insights from the pSoriasis Knowledge IN Canada (SKIN) survey

1 reference

https://api.crossref.org/works/10.1111%2FJDV.12106

21 January 2018

Psychiatric and psychological co-morbidity in patients with dermatologic disorders: epidemiology and management

1 reference

https://api.crossref.org/works/10.1111%2FJDV.12106

21 January 2018

Translating the science of quality of life into practice: What do dermatology life quality index scores mean?

1 reference

https://api.crossref.org/works/10.1111%2FJDV.12106

21 January 2018

Identifiers

10.1111/JDV.12106

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23425140%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23425140%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38083089&oldid=1511097460"